|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | A61K 31/402 | (2006.01) |
| A61K 31/4704 | (2006.01) | ||
| A61P 11/00 | (2006.01) |
| (11) | Number of the document | 2228064 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10164976.2 |
| Date of filing the European patent application | 2005-05-17 | |
| (97) | Date of publication of the European application | 2010-09-15 |
| (45) | Date of publication and mention of the grant of the patent | 2019-12-11 |
| (46) | Date of publication of the claims translation | 2020-03-25 |
| (30) | Number | Date | Country code |
| 0411056 | 2004-05-18 | GB |
| (72) |
Collingwood, Stephen Paul, GB
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Otilija KLIMAITIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Farmacinė kompozicija, kurios sudėtyje yra glikopirolatas ir beta-2 adrenoceptorinis antagonistas |
| Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist |
| Payment date | Validity (years) | Amount | |
| 2024-04-24 | 347.00 EUR |